<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
December 29, 2000
(Date of earliest event reported)
ATRIX LABORATORIES, INC.
------------------------------------------------------
(Exact name of Registrant as specified in its charter)
<TABLE>
<S> <C> <C>
DELAWARE 0-18231 84-1043826
---------------------------- --------------------- ---------------------------------
(State or Other Jurisdiction (Commission File No.) (IRS Employer Identification No.)
of Incorporation)
</TABLE>
2579 MIDPOINT DRIVE, FORT COLLINS, COLORADO 80525
(Address of principal executive offices, including zip code)
(970) 482-5868
---------------------------------------------------
(Registrant's telephone number, including area code)
<PAGE> 2
Item 5. Other Events.
Atrix Laboratories, Inc. (the "Company") completed definitive
agreements with Sanofi-Synthelabo Inc. ("Sanofi-Synthelabo") granting
Sanofi-Synthelabo the exclusive right to market in North America the Company's
Leuprogel(TM) 1-, 3- and 4- month products--a leuprolide acetate product for
subcutaneous depot injection for the treatment of advanced prostate cancer. In
connection with the transaction, the Company and Sanofi-Synthelabo entered into
a Stock Purchase Agreement and a Collaboration, License and Supply Agreement
(the "Collaboration Agreement").
Under the Collaboration Agreement, the Company will receive a license
fee of $8.0 million, in addition to regulatory payments and research and
development funding from Sanofi-Synthelabo. The Company will manufacture the
products and will receive royalties on all sales of such products in North
America. In addition, the Company will be entitled to receive milestone payments
when certain performance criteria are reached for each product. In addition to
the prostate cancer products, Sanofi-Synthelabo received an option to develop a
6-month product for prostate cancer, as well as additional products containing
leuprolide acetate for other indications.
As part of the transaction, Sanofi-Synthelabo also made an initial
equity investment in the Company through the purchase of an aggregate of $15.0
million of the Company's common stock at a premium to market.
The total potential value of the transaction is approximately $60.0
million, exclusive of transfer price and royalties.
The text of Press Release is attached hereto as Exhibit 99.1.
Item 7. Exhibits.
99.1 Text of Press Release dated January 9, 2001.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ATRIX LABORATORIES, INC.
By: /s/ BRIAN G. RICHMOND
-----------------------
Brian G. Richmond
Vice President, Finance
and Assistant Secretary
Date: January 9, 2001
EXHIBIT INDEX
<TABLE>
<CAPTION>
Exhibit
Number Description
------- -----------
<S> <C>
99.1 Text of Press Release dated January 9, 2001.
</TABLE>
